Works Cited

1. National Institute on Aging. Basics of Alzheimer's Disease and Dementia. Available at https://www.nia.nih.gov/health/alzheimers/basics. Last accessed August 14, 2020.

2. Administration on Aging. A Profile of Older Americans: 2019. Rockville, MD: U.S. Department of Health and Human Services; 2019.

3. Abeti R, Abramov AY, Duchen MR. Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain. 2011;134(Pt 6):1658-1672.

4. Alzheimer's Association. 2020 Alzheimer's Disease Facts and Figures. Available at https://www.alz.org/media/Documents/alzheimers-facts-and-figures_1.pdf. Last accessed August 11, 2020.

5. Morris JC. Alzheimer's Disease: Unique, Differentiable and Treatable. 52nd Annual Meeting of the American Academy of Neurology; 2000.

6. Kuller LH, Lopez OL, Becker JT, et al. Risk of dementia and death in the long-term follow-up of the Pittsburgh Cardiovascular Health Study–Cognition Study. Alzheimers Dement. 2016;12(2):170-183.

7. Gist YJ, Hetzel LI, U.S. Census Bureau. We the People: Aging in the United States. Rockville, MD: U.S. Census Bureau; 2004.

8. Alzheimer's Disease Education and Referral Center. 2003 Progress Report on Alzheimer's Disease: Research Advances at NIH. Rockville, MD: U.S. Department of Health and Human Services; 2003.

9. Aarfa A. Drug-Induced Delirium. Available at https://www.clinicaladvisor.com/home/decision-support-in-medicine/hospital-medicine/drug-induced-delirium/. Last accessed August 14, 2020.

10. U.S. Census Bureau. Selected Social Characteristics in the United States, 2018. Available at https://www.census.gov/acs/www/data/data-tables-and-tools/data-profiles/. Last accessed August 14, 2020.

11. U.S. Department of Health and Human Services. Medicare and You 2001. Baltimore, MD: Health Care Financing Administration; 2001.

12. Williams J. Recent breakthroughs in our understanding the genetics of Alzheimer's disease. Int J Neuropsychopharmacol. 2000;3(Suppl 1):S59.

13. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci. 2008;9:768-778.

14. Shapira J, Schlesinger R, Cummings JL. Distinguishing dementias. Am J Nurs. 1986;86(6):698-702.

15. Alzheimer's Association. About. Available at https://www.alz.org/about. Last accessed August 14, 2020.

16. Agency for Health Care Policy and Research. Recognition and Initial Assessment of Alzheimer's Disease and Related Dementias. Rockville, MD: U.S. Department of Health and Human Services; 1996.

17. Alzheimer's Association. What is Dementia? Available at https://www.alz.org/alzheimers-dementia/what-is-dementia. Last accessed August 14, 2020.

18. National Institute on Aging. What Causes Alzheimer's Disease? Available at https://www.nia.nih.gov/health/what-causes-alzheimers-disease. Last accessed August 14, 2020.

19. Vincent AS, Roebuck-Spencer TM, Cernich A. Cognitive changes and dementia risk after traumatic brain injury: implications for aging military personnel. Alzheimers Dement. 2014;10(3 Suppl):S174-S187.

20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.

21. Alzheimer's Association. Types of Dementia. Available at https://www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia. Last accessed August 14, 2020.

22. National Institute of Neurological Disorders and Stroke. Dementia Information Page. Available at https://www.ninds.nih.gov/Disorders/All-Disorders/Dementia-Information-Page. Last accessed August 14, 2020.

23. Schaber P. Occupational Therapy Practice Guidelines for Adults with Alzheimer's Disease and Related Disorders. Bethesda, MD: American Occupational Therapy Association, Inc.; 2010.

24. McCusker J, Cole MG, Voyer P, et al. Environmental factors predict the severity of delirium symptoms in long-term care residents with and without delirium. J Am Geriatr Soc. 2013;61(4):502-511.

25. Arnold E. Sorting out the 3 D's: delirium, dementia, and depression. Nursing. 2004;34(6):36-42.

26. van Asch IF, Nuyen J, Veerbeek MA, Frijters DH, Achterberg WP, Pot AM. The diagnosis of depression and use of antidepressants in nursing home residents with and without dementia. Int J Geriatr Psychiatry. 2013;28(3):312-318.

27. National Institute on Aging. Unraveling the Mystery: The Impact of Alzheimer's Disease. Rockville, MD: U.S. Department of Health and Human Services; 2003.

28. Schwartz J, Fried LB. Legal issues for caregivers of individuals with Alzheimer's disease. In: Zarit SH, Talley RC (eds). Caregiving for Alzheimer's Disease and Related Disorders. New York, NY: Springer; 2013: 165-179.

29. U.S. Department of Health and Human Services. Federal Register. Vol. 56. Baltimore, MD: Health Care Financing Administration; 1991.

30. United States Senate Special Committee on Aging. Untie the Elderly: Quality Care without Restraints. Washington, DC: United States Government Printing Office; 1990.

31. Alzheimer's Disease International. Dementia in the Asia Pacific Region: The Epidemic is Here. Available at https://www.alz.co.uk/research/files/apreportexecsum.pdf. Last accessed August 14, 2020.

32. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Res. 2002;958(1):210-221.

33. Smith M, Buckwalter K. Behaviors associated with dementia: whether resisting care or exhibiting apathy, an older adult with dementia is attempting communication. Nurses and other caregivers must learn to "hear" this language. Am J Nurs. 2005;105(7):40-52.

34. Needham JF. Gerontological Nursing: A Restorative Approach. Albany, NY: Delmar Publishers Inc.; 1993.

35. Academy of Nutrition and Dietetics. Food and Nutrition for Older Adults Promoting Health and Wellness. Chicago, IL: Academy of Nutrition and Dietetics; 2012.

36. Bayles KA, Tomoeda CK. Effective Interventions for Improving Communication Function. Fifth National Alzheimer's Disease Education Conference. Alzheimer's Association; 1996.

37. National Institutes of Health office of Dietary Supplements. Vitamin E: Fact Sheet for Health Professionals. Available at https://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional. Last accessed August 14, 2020.

38. Morris MC, Evans DA, Tangney CC, et al. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr. 2005;81(2):508-514.

39. Abdo CH. Sexuality and couple intimacy in dementia. Curr Opin Psychiatry. 2013;26(6):593-598.

40. Parsons Y. Private acts, public places. Contemp Longterm Care. 1995;18(3):48-49,51,53-55.

41. Barnard ND, Bush AI, Ceccarelli A, et al. Dietary and lifestyle guidelines for the prevention of Alzheimer's disease. Neurobiol Aging. 2014;35(S2):S74-S78.

42. Roy R. Shaping Nutritional Care for the Alzheimer's Client. Fifth National Alzheimer's Disease Education Conference. Alzheimer's Association; 1996.

43. Mohajeri MH, Troesch B, Weber P. Inadequate supply of vitamins and DHA in the elderly: implications for brain aging and Alzheimer's type dementia. Nutrition. 2015;31(2):261-275.

44. Health Care Financing Administration. Nutrition Care Alerts. Washington, DC: American Academy of Family Physicians, the American Dietetic Association, National Council on the Aging; 2003.

45. Ragneskog H, Bråne G, Karlsson I, Kihlgren M. Influence of dinner music on food intake and symptoms common in dementia. Scand J Caring Sci. 1996;10(1):11-17.

46. Brandes RP, Weissmann N, Schröder K. NADPH oxidases in cardiovascular disease. Free Radic Biol Med. 2010;49(5):687-706.

47. Block ML. NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci. 2008;9(Suppl 2):S8.

48. Agency for Health Care Policy and Research. Urinary Incontinence in Adults: Clinical Practice Guideline Update. Rockville, MD: U.S. Department of Health and Human Services; 1996.

49. Ballard C, Corbett A. Agitation and aggression in people with Alzheimer's disease. Curr Opin Psychiatry. 2013;26(3):252-259.

50. Altenhöfer S, Radermacher KA, Kleikers PW, Wingler K, Schmidt HH. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid Redox Signal. 2015;23(5):406-427.

51. Panza F, Solfrizzi V, Imbimbo BP, et al. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. Expert Rev Neurother. 2014;14(9):973-986.

52. Van der Mussele S, Le Bastard N, Saerens J, et al. Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia. Aging Ment Health. 2015;19(3):247-257.

53. Sheline YI, Morris JC, Snyder AZ, et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aß42. J Neurosci. 2010;30(50):17035-17040.

54. Maarouf CL, Daugs ID, Kokjohn TA, et al. The biochemical aftermath of anti-amyloid immunotherapy. Mol Neurodegener. 2010;5:39.

55. Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2008;(3):CD002854.

56. Akanuma K, Meguro K, Meguro M, et al. Improved social interaction and increased anterior cingulate metabolism after group reminiscence with reality orientation approach for vascular dementia. Psychiatry Res. 2011;192(3):183-187.

57. Douglas S, James I, Ballard C. Non-pharmacological interventions in dementia. Advances in Psychiatric Treatment. 2004;10:171-177.

58. Emmelot-Vonk MH, Verhaar HJJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299(1):39-52.

59. Scanland SG, Emershaw LE. Reality orientation and validation therapy: dementia, depression and functional status. J Gerontol Nurs. 1993;19(6):7-11.

60. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag. 2009;5:427-448.

61. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes: evidence reviewed. J Diabetes Sci Technol. 2008;2(6):1101-1113.

62. Donovan C, Dupuis M. Specialized care unit: family and staff perceptions of significant elements. Geriatr Nurs. 2000;21(1):30-33.

63. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699-723.

64. Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry. 2004;75(1):61-71.

65. Smith G. Early-Onset Alzheimer's: When Symptoms Begin Before 65. Available at https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-20048356. Last accessed August 14, 2020.

66. Sadock BJ, Sadock VA. Kaplan & Sadock's Concise Textbook of Clinical Psychiatry. 3rd ed. Philidelphia, PA: Lippincott Williams & Wilkins; 2008.

67. Taipale H, Koponen M, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S. Antipsychotic doses among community-dwelling persons with Alzheimer disease in Finland. J Clin Psychopharmacol. 2014;34(4):435-440.

68. Evans R. Clinical Features and New Therapies for Dementia. 125th Annual Meeting of the American Neurological Association. 2000.

69. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2007;70:1672-1677.

70. Motsinger CD, Perron GA, Lacy TJ. Use of atypical antipsychotic drugs in patients with dementia. Am Fam Physician. 2003;67(11):231-241.

71. Beier MT. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Pharmacotherapy. 2007;27(3):399-411.

72. Seltzer B. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. J Int Med Res. 2006;34(4):339-347.

73. Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA. 2002;99(7):4703-4707.

74. Trinh N, Hoblyn J, Subhanjoy M, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. JAMA. 2003;289(2):210-216.

75. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer's disease and level of cognitive function. Arch Neurol. 2004;61(3):378-384.

76. Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer's disease and normal aging for clinical trials. Arch Neurol. 2004;61(1):59-66.

77. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA. 2000;283(8):1007-1015.

78. Berlau DJ, Corrada MM, Head E, Kawas CH. APOEε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology. 2009;72(9):829-834.

79. Winslow BT, Onysko MK, Stob CM, Hazlewood KA. Treatment of Alzheimer disease. Am Fam Physician. 2011;83(12):1403-1412.

80. Bonte FJ, Harris TS, Roney CA, Hynan LS. Differential diagnosis between Alzheimer's and frontotemporal disease by the posterior cingulate sign. J Nucl Med. 2004;45(5):771-774.

81. Scarmeas N, Zarahn E, Anderson KE, et al. Cognitive reserve-mediated modulation of positron emission tomographic activations during memory tasks in Alzheimer disease. Arch Neurol. 2004;61(1):73-78.

82. Ready RE, Paulsen JS. Neuropsychological studies in geriatric psychiatry. Curr Opin Psychiatry. 2003;16(6):643-648.

83. Gleason OC. Delirium. Am Fam Physician. 2003;67(5):1027-1034.

84. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006;6(1):61-67.

85. Gauthier S, Emire M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19(8):707-714.

86. Silverman DH. Brain F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004;45(4):594-607.

87. Schneider LS. Choosing treatment for Alzheimer's patients and their caregivers. Geriatrics. 2003;58(Suppl 1):3-18.

88. Okamura N, Yanai K. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease. IDrugs. 2010;13(12):890-899.

89. National Institute on Aging. How is Alzheimer's Disease Treated? Available at https://www.nia.nih.gov/health/how-alzheimers-disease-treated. Last accessed August 14, 2020.

90. Alzheimer's Association. Medications for Memory Loss. Available at http://www.alz.org/alzheimers_disease_standard_prescriptions.asp. Last accessed July 29, 2017.

91. Alzheimer's Association. FDA-Approved Treatments for Alzheimer's. Available at http://www.alz.org/national/documents/topicsheet_treatments.pdf. Last accessed August 14, 2020.

92. Lanctôt KL, Herrmann N, Rothenburg L, Eryavec G. Behavioral correlates of GABAergic disruption in Alzheimer's disease.Int Psychogeriatr. 2007;19(1):151-158.

93. Rissman RA, De Blas AL, Armstrong DM. GABA(A) receptors in aging and Alzheimer's disease. J Neurochem. 2007;103(4): 1285-1292.

94. Garcia-Alloza M, Tsang SW, Gil-Bea FJ, et al. Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiol Aging. 2006;27(8):1110-1117.

95. Lipton SA. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets. 2007;8(5):621-632.

96. Alzheimer's Society. Dementia Risk Factors and Prevention. Available at https://www.alzheimers.org.uk/about-dementia/dementia-risk-factors-and-prevention?documentID=102. Last accessed August 14, 2020.

97. Alzheimer's Association. Alternative Treatments. Available at https://www.alz.org/alzheimers-dementia/treatments/alternative-treatments. Last accessed August 14, 2020.

98. McMahon JA, Green, TJ, Skeaff CM, et al. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006;354(26):2764-2772.

99. Kim JM, Stewart R, Kim SW, et al. Changes in folate, vitamin B12, and homocysteine associated with incident dementia. J Neurol Neurosurg Psychiatry. 2008;79(8):864-868.

100. McCarney R, Fisher P, Iliffe S, et al. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry. 2008;23(12):1222-1230.

101. Szekely CA, Gree RC, Breitner JCS, et al. No advantage of Aß42-lowering NSAIDS for prevention of Alzheimer dementia in six pooled cohort studies. Neurology. 2008;70:2291-2298.

102. Tabet N, Feldman H. Ibuprofen for Alzheimer's disease. Cochrane Database Syst Rev. 2003;2:CD004031.

103. Resnick B, Boltz M, Galik E, Pretzer-Aboff I. Restorative Care Nursing for Older Adults: A Guide for All Care Settings. 2nd ed. New York, NY: Springer; 2012.

104. Rajendran L, Schneider A, Schlechtingen G, et al. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science. 2008;320(5875):520-523.

105. Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem. 2008;8(1):54-61.

106. Lichtlen P, Mohajeri MH. Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem. 2008;104(4):859-874.

107. Steinitz M. Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease. Expert Opin Biol Ther. 2008;8(5):633-642.

108. Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med. 2001;7(3):369-372.

109. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem. 2008;104(6):1433-1439.

110. Terwel D, Muyllaert D, Dewachter I, et al. Amyloid activates GSK-3beta to aggravate neuronal taupathy in bigenic mice.Am J Pathol. 2008;172(3):786-798.

111. Thomas G, McGirt MJ, Woodworth G, et al. Baseline neuropsychological profile and cognitive response to cerebrospinal fluid shunting for idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Disord. 2005;20(2-3):163-168.

112. Silverberg GD, Mayo M, Saul T, Fellmann J, Carvalho J, McGuire D. Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study. Neurology. 2008;71(3):202-209.

113. National Institute of Neurological Disorders and Stroke. Disorder Index. Available at https://www.ninds.nih.gov/Disorders/All-Disorders. Last accessed August 14, 2020.

114. Alzheimer's Association. Differential Diagnosis. Available at https://www.alz.org/professionals/health-systems-clinicians/dementia-diagnosis/differential-diagnosis. Last accessed August 14, 2020.

115. Chapman DP, Williams SM, Stine TW, Anda RF, Moore MJ. Dementia and its implications for public health. Prev Chronic Dis. 2006;3(2):A34.

116. Mayo Clinic. Huntington's Disease: Symptoms and Causes. Available at https://www.mayoclinic.org/diseases-conditions/huntingtons-disease/symptoms-causes/syc-20356117. Last accessed August 14, 2020.

117. AETC National Resource Center. HRSA Guide for HIV/AIDS Clinical Care. Available at https://www.aidsetc.org/resource/hrsa-guide-hivaids-clinical-care. Last accessed August 14, 2020.

118. Buchacz K, Patel P, Taylor M. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS. 2004;18(15):2075-2079.

119. Neal M, Wright B. Validation therapy for dementia. Cochrane Database Syst Rev. 2003;2:CD001394.

120. Knudsen RP. Neurosyphilis: Overview of Syphilis of the CNS. Available at https://emedicine.medscape.com/article/1169231-overview. Last accessed August 14, 2020.

121. Fisher Center for Alzheimer's Research Foundation. Top Ten Alzheimer's Signs and Symptoms. Available at https://www.alzinfo.org/understand-alzheimers/top-ten-signs-of-alzheimers. Last accessed August 14, 2020.

122. Amella EJ, Aselage MB. Mealtime difficulties. In: Boltz M, Capezuti E, Fulmer T, Zwicker DA (eds). Geriatric Nursing Protocols for Best Practice. 4th ed. New York, NY: Springer Publishing Company, Inc.; 2012.

123. Alzheimer's Association. Driving and Dementia. Available at http://www.alz.org/national/documents/statements_driving.pdf. Last accessed August 14, 2020.

124. American Medical Association. Physician's Guide to Assessing and Counseling Older Drivers. Available at http://www.nhtsa.gov/people/injury/olddrive/physician_guide/PhysiciansGuide.pdf. Last accessed August 14, 2020.

125. Zanetti O, Oriani M, Geroldi C, et al. Predictors of cognitive improvement after reality orientation in Alzheimer's disease.Age Ageing. 2002;31(3):193-196.

126. Spector A, Orrell M, Davies S, Woods B. Reality orientation for dementia. Cochrane Database Syst Rev. 2007;3:CD001119.

127. National Institute on Aging. Alzheimer's Disease Genetics Fact Sheet. Available at https://www.nia.nih.gov/health/alzheimers-disease-genetics-fact-sheet. Last accessed August 14, 2020.

128. Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S. Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res. 2005;2(3):307-318.

129. McMurtray AM, Ringman J, Chao SZ, Licht E, Saul RE, Mendez MF. Family history of dementia in early-onset versus very late-onset Alzheimer's disease. Int J Geriatr Psychiatry. 2006;21(6):597-598.

130. Coppus AM, Schuur M, Vergeer J, et al. Plasmaβamyloid and the risk of Alzheimer's disease in Down syndrome. Neurobiol Aging. 2012;33(9):1988-1994.

131. Giffard B, Desgranges B, Nore-Mary F, et al. The nature of semantic memory deficits in Alzheimer's disease. Brain. 2001;124(8):1522-1532.

132. Breitner JC, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 1994;44(2):227-232.

133. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer's disease. Arch Gen Psychitry. 2003;60(7):737-746.

134. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias. Arlington, VA: American Psychiatric Association; 2007.

135. U.S. Food and Drug Administration. Information on Conventional Antipsychotics. Available at https://wayback.archive-it.org/7993/20171101120041/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107211.htm. Last accessed August 14, 2020.

136. Phillips CD, Hawes C, Fries BE. Reducing the use of physical restraints in nursing homes: will it increase costs? Am J Public Health. 1993;83(3):342-348.

137. Rochon PA, Normand SL, Gomes T. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168(10):1090-1096.

138. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteoporosis. Available at https://www.bones.nih.gov/health-info/bone/osteoporosis. Last accessed August 14, 2020.

139. Alzheimer's Association. Dementia Care Practice Recommendations for Residential Living. Available at http://www.alz.org/national/documents/brochure_DCPRphases1n2.pdf. Last accessed August 14, 2020.

140. Centers for Disease Control and Prevention. Older Adult Falls. Available at https://www.cdc.gov/homeandrecreationalsafety/falls/index.html. Last accessed August 14, 2020.

141. Kirshner HS. Frontotemporal Dementia and Frontotemporal Lobar Degeneration. Available at https://emedicine.medscape.com/article/1135164-overview. Last accessed August 14, 2020.

142. Vélez L, Selwa LM. Seizure disorders in the elderly. Am Fam Physician. 2003;67:325-332.

143. Oddo S, LaFerla FM. The role of nicotinic acetylcholine receptors in Alzheimer's disease. J Physiol Paris. 2006;99(2-3):172-179.

144. Frisardi V, Solfrizzi V, Capurso C, et al. Aluminum in the diet and Alzheimer's disease: from current epidemiology to possible disease-modifying treatment. J Alzheimers Dis. 2010;20(1):17-30.

145. Rondeau V, Jacqmin-Gadda H, Commenges D, Helmer C, Dartigues JF. Aluminum and silica in drinking water and the risk of Alzheimer's disease or cognitive decline: findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol. 2009;169(4):489-496.

146. Varner JA, Jensen KF, Horvath W, Isaacson RL. Chronic administration of aluminum-fluoride or sodium-fluoride to rats in drinking water: alterations in neuronal and cerebrovascular integrity. Brain Res. 1998;784(1-2):284-298.

147. Wozniak MA, Itzhaki RF. Antiviral agents in Alzheimer's disease: hope for the future? Ther Adv Neurol Disord. 2010;3(3):141-152.

148. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis. 2005;7(1):63-80.

149. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis.2006;9(1):13-33.

150. Cole SL, Vassar R. Linking vascular disorders and Alzheimer's disease: potential involvement of BACE1. Neurobiol Aging. 2009;30(10):1535-1544.

151. Schrag M, Mueller C, Oyoyo U, Kirsch WM. Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol. 2011;94(3):296-306.

152. American Society of Consultant Pharmacists. ASCP policy statement use of antipsychotic medications in nursing facility residents. Consult Pharm. 2011;26(8):583-586.

153. Daviglus ML, Bell CC, Berrettini W, et al. National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline. NIH Consens State Sci Statements. 2010;27(4):1230.

154. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.

155. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.Alzheimers Dement.2011;7(3):263-269.

156. Alzheimer's Association. Stages of Alzheimer's. Available at https://www.alz.org/alzheimers-dementia/stages. Last accessed August 14, 2020.

157. Alzheimer's Association. How is Alzheimer's Disease Diagnosed? Available at https://www.alz.org/alzheimers-dementia/diagnosis. Last accessed August 14, 2020.

158. Tang-Wai DF, Knopman DS, Geda YE, et al. Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. Arch Neurol. 2003;60(12):1777-1781.

159. Hort J, O'Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010;17(10):1236-1248.

160. Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol. 2010;23(3): 185-198.

161. Bonelli RM, Hofmann P, Aschoff A, et al. The influence of psychotropic drugs on cerebral cell death: female neurovulnerability to antipsychotics. Int Clin Psychopharmacol.2005;20(3):145-149.

162. Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245-255.

163. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151-157.

164. Solfrizzi V, Frisardi V, Seripa D, et al. Mediterranean diet in predementia and dementia syndromes. Curr Alzheimer Res. 2011;8(5):520-542.

165. Venneri A, McGeown WJ, Shanks MF. Responders to ChEI treatment of Alzheimer's disease show restitution of normal regional cortical activation. Curr Alzheimer Res.2009;6(2):97-111.

166. Butterfield DA, Barone E, Mancuso C. Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res. 2011;64(3):180-186.

167. Frisardi V, Panza F, Farooqui AA. Late-life depression and Alzheimer's disease: the glutamatergic system inside of this mirror relationship. Brain Res Rev. 2011;67(1-2):344-355.

168. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2):CD008191.

169. Harvey RJ, Skelton-Robinson M, Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry. 2003;74:1206-1209.

170. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systemic review of prospective evidence. Psychol Med. 2009;39:3-11.

171. Ahlskog JE, Geda YE, Graff-Radford NR, Petersen RC. Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. Mayo Clin Proc. 2011;86(9):876-884.

172. Taylor, CA, Greenlund SF, McClure LC, et al. Deaths from Alzheimer's disease—United States, 1999–2014. MMWR. 2017;66:521-526.

173. Gottesman RF, Schneider ALC, Yun Z, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317:1443-1450.

174. Rabin JS, Schulltz AP, Hedden T, et al. Interactive associations of vascular risk and beta-amyloid burden with cognitive decline in clinically normal elderly individuals: findings from the Harvard Aging Brain Study. JAMA Neurol. 2018;75:1124-1131.

175. Brinton R, Yao J, Yin F, et al. Perimenopause as a neurological transition state. Nat Rev Endocrinol. 2015;11:393-405.

176. Mosconi L, Berti V, Quinn C, et al. Sex differences in Alzheimer risk: brain imaging of endocrine vs chronologic aging. Neurology. 2017;89:1382-1390.

177. Demarist TG, Varma V, Estrada D, et al. Biological sex and DNA repair deficiency drive Alzheimer's disease via systemic metabolic remodeling and brain mitochondrial dysfunction. Acta Neuropathol. 2020;140:25-47.

178. Rahman A, Schelbaum E, Hoffman K, et al. Sex-driven modifiers of Alzheimer risk: a multimodality brain imaging study. Neurology. 2020;95(2):e166-e178.

179. Klodian D, Evans D, Rajan K, et al. Healthy lifestyle and the risk of Alzheimer dementia. Neurology. 2020; [Epub ahead of print].

180. Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med. 2018;378:321-330.

181. Bahar-Fuchs A, Martyr A, Goh AMY, et al. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev. 2018;(7):CD013069.

182. Sobol NA, Dali CH, Hogh P, et al. Change in fitness and the relation to change in cognition and neuropsychiatric symptoms after aerobic exercise in patients with mild Alzheimer's disease. J Alzheimers Dis. 2018;65:137-145.

183. Fazio S, Pace D, Maslow K, et al. Alzheimer Association Dementia Care Practice Recommendations. Available at https://www.alz.org/professionals/professional-providers/dementia_care_practice_recommendations. Last accessed August 11, 2020.

Evidence-Based Practice Recommendations Citations

1. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med. 2013;54(3):476-490. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733252. Last accessed August 24, 2020.

2. Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. Eur J Neurol. 2015;22(6):889-898. Available at https://onlinelibrary.wiley.com/doi/full/10.1111/ene.12707. Last accessed August 24, 2020.

3. Amella EJ, Aselage MB. Mealtime difficulties. In: Boltz M, Capezuti E, Fulmer T, Zwicker D (eds). Evidence-Based Geriatric Nursing Protocols for Best Practice. 4th ed. New York, NY: Springer Publishing Company; 2012. Summary retrieved from Guideline Central at https://www.guidelinecentral.com/summaries/assessment-and-management-of-mealtime-difficulties-in-evidence-based-geriatric-nursing-protocols-for-best-practice. Last accessed August 24, 2020.

4. Piersol CV, Jensen L. Occupational Therapy Practice Guidelines for Adults With Alzheimer's Disease and Related Major Neurocognitive Disorders. Bethesda, MD: AOTA Press; 2017. Summary retrieved from Guideline Central at https://www.guidelinecentral.com/share/summary/5b160ada07940. Last accessed August 24, 2020.

5. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19(9):1159-1179. Available at https://www.uems-neuroboard.org/web/images/docs/exam/EAN-guideline-diseases-associated-with-dementia.pdf. Last accessed August 24, 2020.

6. Fletcher K. Recognition and management of dementia. In: Boltz M, Capezuti E, Fulmer T, Zwicker D (eds). Evidence-Based Geriatric Nursing Protocols for Best Practice. 4th ed. New York, NY: Springer Publishing Company; 2012. Summary retrieved from Guideline Central at https://www.guidelinecentral.com/summaries/recognition-and-management-of-dementia-in-evidence-based-geriatric-nursing-protocols-for-best-practice. Last accessed August 24, 2020.


Copyright © 2020 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.